Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.63 |
| ▸ | RORC | P51449 | 1/20 | 0.63 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.51 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | KCNB1 | Q14721 | 3/20 | 0.47 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10943849 | 0.85 | TDP1 (0.67) | TDP1RORCMEN1KMT2ACYP1A2 | |
| SCHEMBL10033006 | 0.84 | ALDH1A1 (0.63) | KMT2ACYP1A2HDAC8HDAC1HDAC6 | |
| SCHEMBL9793651 | 0.83 | TDP1 (0.64) | TDP1RORCMEN1KMT2ACYP1A2 | |
| SCHEMBL10033014 | 0.80 | RORC (0.63) | TDP1RORCHDAC8HDAC1HDAC6 | |
| SCHEMBL5953095 | 0.79 | TDP1 (0.70) | TDP1RORCMEN1KMT2ACYP1A2 | |
| SCHEMBL10874979 | 0.79 | TDP1 (0.70) | TDP1RORCMEN1KMT2ACYP1A2 | |
| SCHEMBL13763482 | 0.79 | TDP1 (0.70) | TDP1RORCMEN1KMT2ACYP1A2 | |
| SCHEMBL730002 | 0.78 | HTR2A (0.51) | TDP1CREBBPHDAC8HDAC1HDAC6 | |
| SCHEMBL2972710 | 0.78 | TDP1 (1.00) | TDP1RORCMEN1KMT2ACYP1A2 | |
| SCHEMBL527474 | 0.78 | TDP1 (0.65) | TDP1RORCMEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-11753365-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2023-09-12 | — | — | US | disclosed |
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2022-11-10 | — | — | US | disclosed |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | NOGRA PHARMA LIMITED (IE) | 2022-02-03 | — | — | US | disclosed |
| US-11046641-B2 | Methods of treating fibrosis | NOGRA PHARMA LIMITED (IE) | 2021-06-29 | — | — | US | disclosed |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | NOGRA PHARMA LTD (IE) | 2021-04-22 | — | — | US | disclosed |
| US-10959970-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2021-03-30 | — | — | US | disclosed |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2020-12-10 | — | — | US | disclosed |
| EP-3744398-A1 | ALKYLAMIDO COMPOUNDS AND USES THEREOF | Nogra Pharma Limited (IE) | 2020-12-02 | — | — | EP | disclosed |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2020-06-18 | — | — | US | disclosed |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2015-02-19 | — | — | US | disclosed |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2015-02-19 | — | — | US | disclosed |
| US-8796334-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8796334-B2 | Methods of treating hair related conditions | NOGRA PHARMA LIMITED (IE) | 2014-08-05 | — | — | US | disclosed |
| US-8754127-B2 | Alkylamido compounds and uses thereof | NOGRA PHARMA LIMITED (IE) | 2014-06-17 | — | — | US | disclosed |
| US-8754127-B2 | Alkylamido compounds and uses thereof | NOGRA PHARMA LIMITED (IE) | 2014-06-17 | — | — | US | disclosed |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | GIULIANI INTERNATIONAL, LTD. (IE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | NOGRA PHARMA LIMITED (IE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220354809-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | TDP1 3825/4885RORC 1314/4885MEN1 4515/4885 |
| US-20200383942-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | TDP1 3825/4885RORC 1314/4885MEN1 4515/4885 |
| US-20150051285-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | TDP1 3825/4885RORC 1314/4885MEN1 4515/4885 |
| US-11753365-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | TDP1 4088/4885RORC 1256/4885MEN1 4490/4885 |
| US-20120053245-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | TDP1 3941/4885RORC 61/4885MEN1 4764/4885 |
| US-20210113505-A1 | METHODS OF TREATING HAIR RELATED CONDITIONS | EBP, AADAT, ALDH7A1 | TDP1 3573/4885RORC 490/4885MEN1 4197/4885 |
| US-10959970-B2 | Methods of treating hair related conditions | PPARA, PPARG, PPARD | TDP1 3941/4885RORC 61/4885MEN1 4764/4885 |
| US-20200188340-A1 | Methods of Treating Hair Related Conditions | PPARA, PPARG, PPARD | TDP1 3941/4885RORC 61/4885MEN1 4764/4885 |
| US-20120053244-A1 | Alkylamido Compounds and Uses Thereof | EGFR, PPARG, ERBB3 | TDP1 3825/4885RORC 1314/4885MEN1 4515/4885 |
| US-11046641-B2 | Methods of treating fibrosis | MMP1, MMP8, FABP2 | TDP1 4088/4885RORC 1256/4885MEN1 4490/4885 |
| US-20220033346-A1 | METHODS OF TREATING FIBROSIS | MMP1, MMP8, FABP2 | TDP1 4088/4885RORC 1256/4885MEN1 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.